CRP and non-Hodgkin lymphoma: A previous report referring to the role of bridging therapy in CAR-T therapy suggested that bridging therapy should be considered for non-Hodgkin’s lymphoma (NHL) patients who have bulky disease (≥10 cm), >1 extranodal site involved, stage 3–4 disease, bone marrow involvement, and elevated pretreatment lactate dehydrogenase and C-reactive protein [39].